Clinical Trials
23 trialsDFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies
Novartis
Pasireotide (SOM230) With or Without Everolimus in Treating Patients With Hormone Resistant, Chemotherapy Naive Prostate Cancer
Thomas Jefferson University
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
OHSU Knight Cancer Institute
First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma
Hoosier Cancer Research Network
Panobinostat and Everolimus in Treating Patients With Metastatic or Unresectable Renal Cell Cancer That Does Not Respond to Treatment With Sunitinib Malate or Sorafenib Tosylate
Roswell Park Cancer Institute
Everolimus Versus Sunitinib in Non-Clear Cell Renal Cell Carcinoma
M.D. Anderson Cancer Center
Akt Inhibitor MK2206 or Everolimus in Treating Patients With Refractory Kidney Cancer
National Cancer Institute (NCI)
Everolimus Therapy in People With Birt-Hogg-Dube Syndrome (BHD)-Associated Kidney Cancer or Sporadic Chromophobe Renal Cancer
National Institutes of Health Clinical Center (CC)
Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy
National Cancer Institute (NCI)
A Study of LY2584702 With Erlotinib or Everolimus in Participants With Solid Tumors
Eli Lilly and Company
Everolimus in Treating Patients With Newly Diagnosed Localized Prostate Cancer
Case Comprehensive Cancer Center
Personalized Targeted Inhibitors Treatment in Renal Cell Cancer
The University of Texas Health Science Center, Houston
ORCHIDEE
Mario Negri Institute for Pharmacological Research
PREV
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
SUNRISES
Associació per a la Recerca Oncologica, Spain
Study of Everolimus Added to Combined Hormonal and Radiation Therapy for High Risk Prostate Cancer
University of Michigan Rogel Cancer Center
Treatment of Refractory Metastatic Renal Cell Carcinoma With Bevacizumab and RAD001 (Everolimus)
Stanford University
Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer
Emory University
Everolimus (RAD001) For Advanced Renal Cell Carcinoma (RCC) Before Kidney Removal
Baylor College of Medicine
POORTOR
Gustave Roussy, Cancer Campus, Grand Paris
RAD001
Heinrich-Heine University, Duesseldorf
ZEBRA
Queen Mary University of London
A Phase 1b Study of SGN-75 in Combination With Everolimus in Patients With Renal Cell Carcinoma
Seagen Inc.